Chimovits Erez
Insider CIK 1706399 · NVUS Director, 10% owner · LOGC Director, 10% owner · ACET Director, 10% owner · PHGE Director, 10% owner · ADRX Director · UPB Director, 10% owner · BRVE Director, 10% owner
Trades across companies
| Ticker | Code | Trade | Filed | Shares | Price | Value | Owned after | |
|---|---|---|---|---|---|---|---|---|
| ADRX ADARx Pharmaceuticals, Inc | C Conversion deriv | 2026-09-28 | 2026-09-30 | 513,067 | — | $0 | 0 | SEC↗ |
| ADRX ADARx Pharmaceuticals, Inc | C Conversion deriv | 2026-09-28 | 2026-09-30 | 7,127,019 | — | $0 | 0 | SEC↗ |
| ADRX ADARx Pharmaceuticals, Inc | C Conversion deriv | 2026-09-28 | 2026-09-30 | 1,333,975 | — | $0 | 0 | SEC↗ |
| ADRX ADARx Pharmaceuticals, Inc | C Conversion deriv | 2026-09-28 | 2026-09-30 | 256,448 | — | $0 | 0 | SEC↗ |
| ADRX ADARx Pharmaceuticals, Inc | C Conversion | 2026-09-28 | 2026-09-30 | 513,067 | — | $0 | 8,974,061 | SEC↗ |
| ADRX ADARx Pharmaceuticals, Inc | C Conversion | 2026-09-28 | 2026-09-30 | 256,448 | — | $0 | 9,230,509 | SEC↗ |
| ADRX ADARx Pharmaceuticals, Inc | P Buy | 2026-09-28 | 2026-09-30 | 61,516 | $17.00 | $1.05M | 9,292,025 | SEC↗ |
| ADRX ADARx Pharmaceuticals, Inc | C Conversion | 2026-09-28 | 2026-09-30 | 1,333,975 | — | $0 | 8,460,994 | SEC↗ |
| ADRX ADARx Pharmaceuticals, Inc | C Conversion | 2026-09-28 | 2026-09-30 | 7,127,019 | — | $0 | 7,127,019 | SEC↗ |
| ADRX ADARx Pharmaceuticals, Inc | C Conversion deriv | 2026-09-28 | 2026-09-30 | 256,448 | — | $0 | 0 | SEC↗ |
| ADRX ADARx Pharmaceuticals, Inc | C Conversion deriv | 2026-09-28 | 2026-09-30 | 513,067 | — | $0 | 0 | SEC↗ |
| ADRX ADARx Pharmaceuticals, Inc | C Conversion deriv | 2026-09-28 | 2026-09-30 | 1,333,975 | — | $0 | 0 | SEC↗ |
| ADRX ADARx Pharmaceuticals, Inc | C Conversion deriv | 2026-09-28 | 2026-09-30 | 7,127,019 | — | $0 | 0 | SEC↗ |
| ADRX ADARx Pharmaceuticals, Inc | P Buy | 2026-09-28 | 2026-09-30 | 61,516 | $17.00 | $1.05M | 9,292,025 | SEC↗ |
| ADRX ADARx Pharmaceuticals, Inc | C Conversion | 2026-09-28 | 2026-09-30 | 256,448 | — | — | 9,230,509 | SEC↗ |
| ADRX ADARx Pharmaceuticals, Inc | C Conversion | 2026-09-28 | 2026-09-30 | 513,067 | — | — | 8,974,061 | SEC↗ |
| ADRX ADARx Pharmaceuticals, Inc | C Conversion | 2026-09-28 | 2026-09-30 | 1,333,975 | — | — | 8,460,994 | SEC↗ |
| ADRX ADARx Pharmaceuticals, Inc | C Conversion | 2026-09-28 | 2026-09-30 | 7,127,019 | — | — | 7,127,019 | SEC↗ |
| BRVE Braveheart Bio, Inc. | C Conversion deriv | 2026-08-07 | 2026-08-11 | 40,000,000 | — | $0 | 0 | SEC↗ |
| BRVE Braveheart Bio, Inc. | P Buy | 2026-08-07 | 2026-08-11 | 273,333 | $18.00 | $4.92M | 273,333 | SEC↗ |
| BRVE Braveheart Bio, Inc. | P Buy | 2026-08-07 | 2026-08-11 | 1,666,667 | $18.00 | $30.00M | 11,901,826 | SEC↗ |
| BRVE Braveheart Bio, Inc. | C Conversion | 2026-08-07 | 2026-08-11 | 9,132,420 | — | $0 | 10,235,159 | SEC↗ |
| BRVE Braveheart Bio, Inc. | C Conversion deriv | 2026-08-07 | 2026-08-11 | 40,000,000 | — | $0 | 0 | SEC↗ |
| BRVE Braveheart Bio, Inc. | P Buy | 2026-08-07 | 2026-08-11 | 273,333 | $18.00 | $4.92M | 273,333 | SEC↗ |
| BRVE Braveheart Bio, Inc. | P Buy | 2026-08-07 | 2026-08-11 | 1,666,667 | $18.00 | $30.00M | 11,901,826 | SEC↗ |
| BRVE Braveheart Bio, Inc. | C Conversion | 2026-08-07 | 2026-08-11 | 9,132,420 | — | — | 10,235,159 | SEC↗ |
| BRVE Braveheart Bio, Inc. | A Award deriv | 2026-08-05 | 2026-08-07 | 30,000 | — | $0 | 30,000 | SEC↗ |
| BRVE Braveheart Bio, Inc. | A Award deriv | 2026-08-05 | 2026-08-07 | 30,000 | — | $0 | 30,000 | SEC↗ |
| UPB Upstream Bio, Inc. | A Award deriv | 2026-06-09 | 2026-06-11 | 17,096 | — | $0 | 17,096 | SEC↗ |
| UPB Upstream Bio, Inc. | A Award deriv | 2025-06-10 | 2025-06-12 | 17,096 | — | $0 | 17,096 | SEC↗ |
| UPB Upstream Bio, Inc. | C Conversion deriv | 2024-10-15 | 2024-10-17 | 789,833 | — | $0 | 0 | SEC↗ |
| UPB Upstream Bio, Inc. | C Conversion deriv | 2024-10-15 | 2024-10-17 | 524,500 | — | $0 | 0 | SEC↗ |
| UPB Upstream Bio, Inc. | C Conversion deriv | 2024-10-15 | 2024-10-17 | 2,098,000 | — | $0 | 0 | SEC↗ |
| UPB Upstream Bio, Inc. | C Conversion deriv | 2024-10-15 | 2024-10-17 | 197,456 | — | $0 | 0 | SEC↗ |
| UPB Upstream Bio, Inc. | P Buy | 2024-10-15 | 2024-10-17 | 660,000 | $17.00 | $11.22M | 4,554,873 | SEC↗ |
| UPB Upstream Bio, Inc. | C Conversion | 2024-10-15 | 2024-10-17 | 2,887,833 | — | $0 | 3,894,873 | SEC↗ |
| UPB Upstream Bio, Inc. | P Buy | 2024-10-15 | 2024-10-17 | 165,000 | $17.00 | $2.81M | 1,138,716 | SEC↗ |
| UPB Upstream Bio, Inc. | C Conversion | 2024-10-15 | 2024-10-17 | 721,956 | — | $0 | 973,716 | SEC↗ |
| UPB Upstream Bio, Inc. | A Award deriv | 2024-10-10 | 2024-10-15 | 17,096 | — | $0 | 17,096 | SEC↗ |
| PHGE BiomX Inc. | X Exercise deriv | 2024-05-15 | 2024-05-20 | 9,280,408 | — | $0 | 0 | SEC↗ |
| PHGE BiomX Inc. | X Exercise | 2024-05-15 | 2024-05-20 | 9,280,408 | $0.24 | $2.23M | 13,797,997 | SEC↗ |
| PHGE BiomX Inc. | S Sale | 2024-05-15 | 2024-05-20 | 24,344 | $0.38 | $9.3K | 13,773,653 | SEC↗ |
| PHGE BiomX Inc. | P Buy deriv | 2024-03-15 | 2024-03-19 | 4,327 | — | $0 | 4,327 | SEC↗ |
| PHGE BiomX Inc. | P Buy deriv | 2024-03-15 | 2024-03-19 | 2,163,500 | — | $0 | 2,163,500 | SEC↗ |
| ACET Adicet Bio, Inc. | P Buy | 2023-06-27 | 2023-06-29 | 125,000 | $2.09 | $261.2K | 1,027,885 | SEC↗ |
| ACET Adicet Bio, Inc. | P Buy | 2023-06-27 | 2023-06-29 | 250,000 | $2.09 | $522.5K | 646,657 | SEC↗ |
| ACET Adicet Bio, Inc. | P Buy | 2023-06-27 | 2023-06-29 | 442,000 | $2.09 | $923.8K | 5,685,259 | SEC↗ |
| ACET Adicet Bio, Inc. | P Buy | 2023-06-27 | 2023-06-29 | 58,000 | $2.09 | $121.2K | 748,054 | SEC↗ |
| PHGE BiomX Inc. | P Buy deriv | 2023-02-27 | 2023-03-17 | 1,789,959 | — | $0 | 1,789,959 | SEC↗ |
| PHGE BiomX Inc. | P Buy | 2023-02-27 | 2023-03-17 | 348,000 | $0.25 | $87.0K | 3,161,489 | SEC↗ |
| ACET Adicet Bio, Inc. | A Award | 2021-02-12 | 2021-02-18 | 420,299 | $13.00 | $5.46M | 5,243,259 | SEC↗ |
| ACET Adicet Bio, Inc. | A Award | 2021-02-12 | 2021-02-18 | 104,050 | $13.00 | $1.35M | 396,657 | SEC↗ |
| LOGC LogicBio Therapeutics, Inc | P Buy | 2020-10-01 | 2020-10-05 | 296,296 | $6.00 | $1.78M | 296,296 | SEC↗ |
| LOGC LogicBio Therapeutics, Inc | P Buy | 2020-10-01 | 2020-10-05 | 639,212 | $6.00 | $3.84M | 4,126,972 | SEC↗ |
| LOGC LogicBio Therapeutics, Inc | P Buy | 2020-10-01 | 2020-10-05 | 545,974 | $6.00 | $3.28M | 3,524,997 | SEC↗ |
| ACET Adicet Bio, Inc. | A Award deriv | 2020-09-17 | 2020-09-17 | 30,000 | — | $0 | 30,000 | SEC↗ |
| ACET Adicet Bio, Inc. | A Award | 2020-09-15 | 2020-09-17 | 902,885 | — | $0 | 902,855 | SEC↗ |
| ACET Adicet Bio, Inc. | A Award | 2020-09-15 | 2020-09-17 | 292,607 | — | $0 | 292,607 | SEC↗ |
| LOGC LogicBio Therapeutics, Inc | A Award deriv | 2020-06-19 | 2020-06-23 | 2,513 | — | $0 | 2,513 | SEC↗ |
| LOGC LogicBio Therapeutics, Inc | A Award deriv | 2020-06-19 | 2020-06-23 | 10,000 | — | $0 | 10,000 | SEC↗ |
| PHGE BiomX Inc. | A Award deriv | 2020-03-25 | 2020-03-27 | 16,000 | — | $0 | 16,000 | SEC↗ |
| NVUS Novus Therapeutics, Inc. | S Sale deriv | 2020-01-14 | 2020-02-25 | 646,204 | $0.20 | $129.2K | 0 | SEC↗ |
| NVUS Novus Therapeutics, Inc. | S Sale deriv | 2020-01-14 | 2020-02-25 | 646,204 | $0.20 | $129.2K | 0 | SEC↗ |
| LOGC LogicBio Therapeutics, Inc | A Award deriv | 2019-12-19 | 2019-12-20 | 10,869 | — | $0 | 10,869 | SEC↗ |
| PHGE BiomX Inc. | P Buy | 2019-12-19 | 2019-12-20 | 3,500 | $8.90 | $31.1K | 2,313,489 | SEC↗ |
| PHGE BiomX Inc. | P Buy | 2019-12-18 | 2019-12-20 | 500 | $8.93 | $4.5K | 2,309,989 | SEC↗ |
| PHGE BiomX Inc. | P Buy | 2019-12-11 | 2019-12-12 | 5,400 | $8.92 | $48.2K | 2,309,489 | SEC↗ |
| PHGE BiomX Inc. | P Buy | 2019-12-10 | 2019-12-12 | 3,400 | $8.75 | $29.8K | 2,304,089 | SEC↗ |
| PHGE BiomX Inc. | P Buy | 2019-12-09 | 2019-12-09 | 6,000 | $8.68 | $52.1K | 2,300,689 | SEC↗ |
| PHGE BiomX Inc. | P Buy | 2019-12-06 | 2019-12-09 | 800 | $8.00 | $6.4K | 2,294,689 | SEC↗ |
| PHGE BiomX Inc. | P Buy | 2019-12-05 | 2019-12-09 | 3,400 | $7.99 | $27.2K | 2,293,889 | SEC↗ |
| NVUS Novus Therapeutics, Inc. | A Award deriv | 2019-07-11 | 2019-07-15 | 20,000 | — | $0 | 20,000 | SEC↗ |
| NVUS Novus Therapeutics, Inc. | P Buy deriv | 2019-05-02 | 2019-05-06 | 646,204 | — | $0 | 646,204 | SEC↗ |
| NVUS Novus Therapeutics, Inc. | P Buy deriv | 2019-05-02 | 2019-05-06 | 646,204 | — | $0 | 646,204 | SEC↗ |
| NVUS Novus Therapeutics, Inc. | P Buy | 2019-05-02 | 2019-05-06 | 646,204 | $3.10 | $2.00M | 3,183,314 | SEC↗ |
| LOGC LogicBio Therapeutics, Inc | C Conversion deriv | 2018-10-23 | 2018-10-25 | 3,046,943 | — | $0 | 0 | SEC↗ |
| LOGC LogicBio Therapeutics, Inc | C Conversion deriv | 2018-10-23 | 2018-10-25 | 2,678,571 | — | $0 | 0 | SEC↗ |
| LOGC LogicBio Therapeutics, Inc | P Buy | 2018-10-23 | 2018-10-25 | 490,000 | $10.00 | $4.90M | 3,487,760 | SEC↗ |
| LOGC LogicBio Therapeutics, Inc | C Conversion | 2018-10-23 | 2018-10-25 | 2,997,760 | — | $0 | 2,997,760 | SEC↗ |
| LOGC LogicBio Therapeutics, Inc | A Award deriv | 2018-10-18 | 2018-10-22 | 24,102 | — | $0 | 24,102 | SEC↗ |